Bio Green Med Solution, Inc. (BGMS)
| Market Cap | 5.33M -91.4% |
| Revenue (ttm) | 1.53M +10,792.9% |
| Net Income | -14.23M |
| EPS | -4.11 |
| Shares Out | 5.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,508 |
| Open | 0.9750 |
| Previous Close | 0.9700 |
| Day's Range | 0.9650 - 1.0700 |
| 52-Week Range | 0.7303 - 29.0500 |
| Beta | -0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About BGMS
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It is also involved in research and development of pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. Bio Green Med Solution, Inc. was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Financial Performance
In 2025, Bio Green Med Solution's revenue was $747,000, an increase of 1637.21% compared to the previous year's $43,000. Losses were -$14.09 million, 25.7% more than in 2024.
Financial StatementsNews
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety p...
Bio Green Med Solution Earnings release: Q1 2026
Bio Green Med Solution released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Bio Green Med Solution Quarterly report: Q1 2026
Bio Green Med Solution has published its Q1 2026 quarterly earnings report on May 14, 2026.
Bio Green Med Solution Proxy statement: Proxy filing
Bio Green Med Solution filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Bio Green Med Solution Proxy statement: Proxy filing
Bio Green Med Solution filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company e...
Bio Green Med Solution Annual report: Q4 2025
Bio Green Med Solution has published its Q4 2025 annual report on March 30, 2026.
Bio Green Med Solution Earnings release: Q4 2025
Bio Green Med Solution released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update
KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified c...
Bio Green Med Solution Quarterly report: Q3 2025
Bio Green Med Solution has published its Q3 2025 quarterly earnings report on November 13, 2025.
Bio Green Med Solution Earnings release: Q3 2025
Bio Green Med Solution released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Bio Green Med Solution Proxy statement: Proxy Filing
Bio Green Med Solution filed a proxy statement on August 25, 2025, providing details for shareholder voting and corporate governance matters.
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative m...
Bio Green Med Solution Quarterly report: Q2 2025
Bio Green Med Solution has published its Q2 2025 quarterly earnings report on August 13, 2025.
Bio Green Med Solution Earnings release: Q2 2025
Bio Green Med Solution released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...
Bio Green Med Solution Registration statement: Registration Filing
Bio Green Med Solution filed a registration statement on July 31, 2025, providing details about a securities offering with the SEC.
Bio Green Med Solution Registration statement: Registration Filing
Bio Green Med Solution filed a registration statement on July 24, 2025, providing details about a securities offering with the SEC.
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults -
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative m...
Cyclacel Pharmaceuticals Announces Stock Split
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative m...
Bio Green Med Solution Proxy statement: Proxy Filing
Bio Green Med Solution filed a proxy statement on June 25, 2025, providing details for shareholder voting and corporate governance matters.
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today a...
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovativ...
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative me...